ANAPTYSBIO, INC (ANAB)

Current Report Filed: 2026-03-27

Key Insights

• AnaptysBio, Inc. announced the approval by its board of directors to distribute all outstanding shares of First Tracks Biotherapeutics, Inc. (SpinCo) to AnaptysBio shareholders as a pro rata dividend.
• First Tracks Biotherapeutics has entered into a purchase agreement to issue and sell 5,791,478 shares of its common stock for approximately $80 million in gross proceeds, as well as 4,705,576 secondary shares from a selling stockholder.
• The private placement of First Tracks Biotherapeutics shares is expected to close immediately after the spin-off from AnaptysBio, which is planned for April 20, 2026.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-03-27

Key Insights

• The reporting person, Daniel Faga, acquired 34,300 performance-based restricted stock units (PSUs) on March 25, 2026, indicating an incentive-based compensation structure aligned with the company's performance.
• Faga sold a total of 11,379 shares on March 27, 2026 to cover tax withholding obligations, suggesting he is actively managing his equity position in the company.
• The reported sales were executed at a range of prices, with the weighted average prices provided, offering transparency into the transaction details.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-16

Key Insights

• Magda Marquet, a director at AnaptysBio, exercised 11,000 stock options and then sold 11,000 shares of common stock on January 15, 2026.
• The stock sales were made at weighted average prices of $48.12 and $48.85 per share, suggesting Marquet may be capitalizing on the stock's recent price appreciation.
• In addition to the exercised options, Marquet holds additional stock options to purchase up to 70,104 shares, which could indicate further potential insider selling in the future.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Current Report Filed: 2026-01-09

Key Insights

• AnaptysBio expects to report approximately $310 million in cash and cash equivalents as of December 31, 2025, indicating a strong financial position.
• The company plans to provide preliminary, unaudited financial information in an upcoming presentation, though the final audited results may differ.
• Investors should watch for the full audited financial statements to be released, as the preliminary information may not provide a complete picture of the company's performance.

Sentiment: Positive Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• John A. Orwin, a director of AnaptysBio, Inc. (ANAB), acquired 8,250 stock options and 6,000 restricted stock units on January 6, 2026, indicating potential confidence in the company's future.
• The stock options have a 10-year expiration date and vest monthly over the next year, while the restricted stock units vest fully on the date of the company's 2027 annual meeting, aligning Orwin's interests with long-term shareholder value.
• The significant insider buying activity, both in terms of the number of shares and the vesting schedule, suggests Orwin believes in the company's growth prospects and may signal a positive outlook for ANAB's future performance.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• The reporting person, J. Anthony Ware, is a director at AnaptysBio, Inc. (ANAB), indicating involvement in the company's management and operations.
• Ware has been granted 5,500 stock options with an exercise price of $43.91 and 4,000 restricted stock units (RSUs), which align his interests with those of shareholders.
• The vesting schedules for the options and RSUs suggest Ware's long-term commitment to the company, as the options vest monthly over 12 months and the RSUs vest fully at the 2027 annual meeting.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• The reporting person, John P. Schmid, acquired 5,500 stock options and 4,000 restricted stock units (RSUs) on January 6, 2026, indicating potential confidence in the company's future performance.
• The stock options have a vesting schedule of 1/12th per month starting February 6, 2026, while the RSUs vest 100% on the date of the company's 2027 annual meeting, subject to the reporting person's continued service.
• The reporting person's direct beneficial ownership of the company's common stock has increased to 9,500 shares following this transaction.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• The reporting person, Renton Hollings, has been granted 5,500 stock options and 4,000 restricted stock units (RSUs) as part of their compensation as a director of AnaptysBio, Inc.
• The stock options vest monthly over 12 months, while the RSUs vest fully at the company's 2027 annual meeting, subject to the reporting person's continued service.
• This insider transaction suggests ongoing alignment between the reporting person and the company's long-term success, as they are being incentivized through equity-based compensation.

Sentiment: Positive Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• Magda Marquet, a director of AnaptysBio, Inc. (ANAB), acquired 5,500 stock options and 4,000 restricted stock units on January 6, 2026, indicating insider investment in the company.
• The stock options vest monthly over the next 12 months, while the restricted stock units vest fully on the date of the company's 2027 annual meeting, suggesting a long-term commitment from the director.
• The transaction value is significant, with the stock options having an exercise price of $43.91 and the restricted stock units representing 4,000 shares of the company's common stock.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• Rita Jain, a director at AnaptysBio, Inc., acquired 5,500 stock options and 4,000 restricted stock units on January 6, 2026, indicating potential confidence in the company's long-term prospects.
• The stock options have a 10-year term and vest monthly over the next year, while the restricted stock units vest fully at the 2027 annual meeting, suggesting a medium-term investment horizon.
• Insider buying, especially by a director, can be a positive signal for investors, as it may indicate management's belief in the company's future performance.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• Dennis M. Fenton, a director of AnaptysBio, Inc. (ANAB), has been granted 5,500 stock options and 4,000 restricted stock units (RSUs) on January 6, 2026. This suggests ongoing commitment and alignment of interests between the director and the company.
• The stock options vest monthly over a 1-year period, while the RSUs vest in full on the date of the company's 2027 annual meeting, subject to Fenton's continued service. This vesting schedule incentivizes long-term engagement and performance.
• The reported transactions provide insight into the company's compensation practices and the board's efforts to attract and retain talented directors like Fenton, which could be viewed positively by investors.

Sentiment: Positive Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• The reporting person, Dennis Mulroy, acquired 21,400 restricted stock units (RSUs) and 29,000 stock options, indicating increased equity compensation and alignment with shareholder interests.
• Mulroy sold 1,908 shares to cover tax withholding obligations, suggesting he is actively managing his equity position while holding a significant number of shares.
• The vesting schedules for the RSUs and stock options suggest a long-term incentive structure, with the majority of the awards vesting over multiple years, aligning management's interests with long-term company performance.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• Daniel Faga, the President and CEO of ANAPTYSBIO, INC, acquired 17,850 shares through the vesting of restricted stock units (RSUs) and an additional 98,600 RSUs and 133,400 stock options, indicating his long-term commitment to the company.
• Faga sold 9,202 shares to cover tax withholding obligations, which is a common practice for insiders when their equity awards vest.
• The RSUs vest annually over 4 years, and the stock options vest over 4 years as well, aligning Faga's incentives with long-term shareholder value creation.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• The reporting person, Paul F. Lizzul, who is the Chief Medical Officer of ANAPTYSBIO, INC, acquired 21,400 restricted stock units (RSUs) and 29,000 stock options on January 6, 2026, indicating a positive long-term view on the company's prospects.
• Lizzul also exercised 6,145 RSUs and sold 2,235 shares on January 6 and 7, 2026, respectively, to cover tax withholding obligations, suggesting he is holding on to a significant portion of his equity stake in the company.
• The vesting schedules for the RSUs and stock options indicate that Lizzul's compensation is aligned with the company's long-term performance, as the awards vest over multiple years.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-08

Key Insights

• Eric J. Loumeau, the Chief Legal Officer of AnaptysBio, Inc., exercised 5,545 restricted stock units (RSUs) and sold 9,639 shares of common stock to cover tax withholding obligations.
• Loumeau also received a grant of 17,100 new RSUs and 23,200 stock options, indicating continued commitment and incentive alignment with the company's long-term performance.
• The insider selling appears to be routine tax-related transactions and not indicative of a broader negative sentiment, as Loumeau maintains a significant direct ownership stake of 9,157 shares.

Sentiment: Neutral Significance: 4/10

View Original Filing →